Target family: Bromodomain kinase (BRDK) family (type: enzyme)
Target: bromodomain containing 4

Ligand: XY-06-007 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pIC50
Reference (Journal): Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Published in: Eur J Med Chem

Ligand: XD14 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pKd
Reference (Journal): 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
Published in: Angew Chem Int Ed Engl

Ligand: XD1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.340000152587891 pKd
Reference (Journal): 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
Published in: Angew Chem Int Ed Engl

Ligand: WNY0824 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.960000038146973 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Published in: Eur J Med Chem

Ligand: PFI-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.659999847412109 pIC50
Reference (Journal): Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
Published in: J Med Chem

Ligand: pelabresib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.409999847412109 pIC50
Reference (Journal): Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Published in: J Med Chem

Ligand: N-methyl-2-pyrrolidone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 2.2200000286102295 pIC50
Reference (Journal): The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.
Published in: Cell Rep

Ligand: NHWD-870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.569999694824219 pIC50
Reference (Journal): Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction.
Published in: Nat Commun

Ligand: MZ1 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pKd
Reference (Journal): Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
Published in: J Med Chem

Ligand: MS436 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.
Published in: J Med Chem

Ligand: MS417 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.
Published in: J Biol Chem

Ligand: molibresib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.440000057220459 pIC50
Reference (Journal): Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Published in: J Med Chem

Ligand: molibresib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pEC50
Reference (Journal): Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Published in: J Med Chem

Ligand: mivebresib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Patent): Bromodomain inhibitors

Ligand: LY 294002 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pKd
Reference (Journal): The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
Published in: ACS Chem Biol

Ligand: (+)-JQ1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKd
Reference (Journal): Selective inhibition of BET bromodomains.
Published in: Nature

Ligand: isoxazole azepine compound 3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
Published in: ACS Med Chem Lett

Ligand: I-BET282 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
Published in: J Med Chem

Ligand: I-BET151 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Published in: Nature

Ligand: GW841819X (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.809999942779541 pIC50
Reference (Journal): Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Published in: J Med Chem

Ligand: GSK852 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
Published in: J Med Chem

Ligand: GSK852 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.5 pKd
Reference (Journal): Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
Published in: J Med Chem

Ligand: fedratinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2019), EMA (2021)
Primary target: no
Median affinity: 6.789999961853027 pKd
Reference (Journal): Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Published in: Nat Chem Biol

Ligand: dual BRD4/PLK1 inhibitor 23 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Published in: J Med Chem

Ligand: dBET6 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Published in: Mol Cell

Ligand: CPI-203 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.429999828338623 pIC50
Reference (Journal): BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.
Published in: Proc Natl Acad Sci USA

Ligand: compound 9 [PMID: 23517011] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.429999828338623 pIC50
Reference (Journal): Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
Published in: J Med Chem

Ligand: compound 7d [PMID: 25703523] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.329999923706055 pKd
Reference (Journal): 9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain.
Published in: J Med Chem

Ligand: compound 6 [PMID: 30125504] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.590000152587891 pIC50
Reference (Journal): Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Published in: J Med Chem

Ligand: compound 4d [PMID: 21851057] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.320000171661377 pIC50
Reference (Journal): 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Published in: J Med Chem

Ligand: compound 3 [PMID: 25408830] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.099999904632568 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: compound 38 [PMID: 24000170] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.5 pIC50
Reference (Journal): Naphthyridines as novel BET family bromodomain inhibitors.
Published in: ChemMedChem

Ligand: compound 36 [PMID: 24000170] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pIC50
Reference (Journal): Naphthyridines as novel BET family bromodomain inhibitors.
Published in: ChemMedChem

Ligand: compound 2 [PMID: 25408830] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.699999809265137 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: compound 25ap [PMID: 37796543] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.029999732971191 pIC50
Reference (Journal): Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
Published in: J Med Chem

Ligand: compound 1 [PMID: 25408830] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 4.099999904632568 pIC50
Reference (Journal): 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.
Published in: ACS Med Chem Lett

Ligand: compound 15 [Hay et al., 2013] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.900000095367432 pIC50
Reference (Journal): The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains.
Published in: Medchemcomm

Ligand: compound 11h [PMID: 29808961] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Published in: ChemMedChem

Ligand: colchicine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: no
Median affinity: 4.699999809265137 pKd
Reference (Journal): 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
Published in: Angew Chem Int Ed Engl

Ligand: BzT-7 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.190000057220459 pKd
Reference (Journal): Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
Published in: Bioorg Med Chem

Ligand: BMS-986158 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.960000038146973 pIC50
Reference (Journal): Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.
Published in: J Med Chem

Ligand: BI-2536 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.429999828338623 pKd
Reference (Journal): Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Published in: Nat Chem Biol

Ligand: ARV-771 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.119999885559082 pKd
Reference (Journal): PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Published in: Proc Natl Acad Sci USA

Ligand: apabetalone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Published in: PLoS ONE

Ligand: amredobresib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Patent): Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors